Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) - Episode 7

The Potential Impact of Tislelizumab on First-Line ESCC Treatment

January 30, 2023

Harry H. Yoon, MD, Nabil F. Saba, MD, FACP

Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.

EP. 1: Trends in ESCC Incidence and Observations from Clinical Practice

EP. 2: Approaches to Biomarker Testing for ESCC

EP. 3: The Impact of Biomarker Results on Prognosis and Treatment Decision-Making

EP. 4: First-Line Options for Advanced/Metastatic Disease

EP. 5: Insights on ESCC First-Line Treatment Selection

EP. 6: RATIONALE-306 Data on Tislelizumab in ESCC

Now Viewing

EP. 7: The Potential Impact of Tislelizumab on First-Line ESCC Treatment

EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers

EP. 9: A Look Towards the Future of ESCC